Fig. 2From: Mutational status predicts the risk of thromboembolic events in lung adenocarcinomaSensitivity analysis considering risk of thromboembolism for treatments received by patients with lung adenocarcinoma in stage IV during the study period. Calculated with a Cox regression model including only patients with lung adenocarcinoma in stage IV and considering chemotherapy alone as reference for the analysis. Demonstrates the difference in event-free survival between patients treated with tyrosine kinase inhibitors (TKI) alone or in combination with other treatments compared to other treatments not including TKI. CPT: chemotherapy; TKI: tyrosine kinase inhibitors. Cumulative event-free survival variable: time before the first thromboembolic eventBack to article page